Aspire Biopharma Holdings (ASBP) Liabilities and Shareholders Equity (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $13.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1268.53% year-over-year to $13.5 million in Q2 2026; TTM through Jun 2026 was $24.4 million, a 685.48% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 786.66% from the prior year.
• Liabilities and Shareholders Equity was $13.5 million for Q2 2026 at Aspire Biopharma Holdings, up from $7.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $303.1 million in Q1 2023 and troughed at $147989.0 in Q4 2024.
• A 5-year average of $94.7 million and a median of $19.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 102273.98% in 2022 and slumped 99.26% in 2024, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $300.2 million in 2022, then sank by 93.34% to $20.0 million in 2023, then tumbled by 99.26% to $147989.0 in 2024, then soared by 786.66% to $1.3 million in 2025, then soared by 931.92% to $13.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $13.5 million (Q2 2026), $7.1 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.